Combined Biomarker System Predicts Prognosis in Patients with Metastatic Oral Squamous Cell Carcinoma.
E-cadherin
EMMPRIN
connexin 43
disease-free survival
epithelial-to-mesenchymal transition
metastasis
oral squamous cell carcinoma
overall survival
prognosis
vimentin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Oct 2023
10 Oct 2023
Historique:
received:
04
09
2023
revised:
27
09
2023
accepted:
09
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Metastatic oral squamous cell carcinoma (OSCC) is associated with poor patient prognosis. Metastasis is a complex process involving various proteins, tumor cell alterations, including changes attributable to the epithelial-to-mesenchymal transition (EMT) process, and interactions with the tumor microenvironment (TME). In this study, we investigate a combined protein marker system consisting of connexin 43 (Cx43), EMMPRIN (CD147), E-cadherin, and vimentin, with a focus on their roles in the invasive metastatic progression of OSCC and their potential utility in predicting prognosis. We conducted an immunohistochemical analysis to assess the protein expression profiles of Cx43, EMMPRIN, E-cadherin, and vimentin using tissue samples obtained from 24 OSCC patients. The metastatic process was mapped through different regions of interest (ROIs), including adjacent healthy oral mucosa (OM), center of primary OSCC, invasive front (IF), and local cervical lymph node metastases (LNM). The primary clinical endpoints were disease-free survival (DFS) and overall survival (OS). Substantial changes in the expression profiles of the different marker proteins were observed among the different ROIs, with all The combined marker system exhibited a significant ability to predict patient prognosis. An increase in EMMPRIN expression toward the IF showed the strongest effect and could be an interesting new antimetastatic therapy approach.
Sections du résumé
BACKGROUND
BACKGROUND
Metastatic oral squamous cell carcinoma (OSCC) is associated with poor patient prognosis. Metastasis is a complex process involving various proteins, tumor cell alterations, including changes attributable to the epithelial-to-mesenchymal transition (EMT) process, and interactions with the tumor microenvironment (TME). In this study, we investigate a combined protein marker system consisting of connexin 43 (Cx43), EMMPRIN (CD147), E-cadherin, and vimentin, with a focus on their roles in the invasive metastatic progression of OSCC and their potential utility in predicting prognosis.
METHODS
METHODS
We conducted an immunohistochemical analysis to assess the protein expression profiles of Cx43, EMMPRIN, E-cadherin, and vimentin using tissue samples obtained from 24 OSCC patients. The metastatic process was mapped through different regions of interest (ROIs), including adjacent healthy oral mucosa (OM), center of primary OSCC, invasive front (IF), and local cervical lymph node metastases (LNM). The primary clinical endpoints were disease-free survival (DFS) and overall survival (OS).
RESULTS
RESULTS
Substantial changes in the expression profiles of the different marker proteins were observed among the different ROIs, with all
CONCLUSIONS
CONCLUSIONS
The combined marker system exhibited a significant ability to predict patient prognosis. An increase in EMMPRIN expression toward the IF showed the strongest effect and could be an interesting new antimetastatic therapy approach.
Identifiants
pubmed: 37894290
pii: cancers15204924
doi: 10.3390/cancers15204924
pmc: PMC10605069
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Head Neck. 2020 Mar;42(3):569-584
pubmed: 31750584
Front Med. 2018 Aug;12(4):361-373
pubmed: 30043221
J Oral Pathol Med. 2020 Nov;49(10):1019-1029
pubmed: 32740991
Br J Cancer. 2015 Jul 14;113(2):259-67
pubmed: 26135897
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2019 Apr 01;11(4):
pubmed: 30939738
Biomolecules. 2020 Dec 10;10(12):
pubmed: 33321749
Int J Oncol. 2014 Jul;45(1):273-81
pubmed: 24788723
Adv Cancer Res. 2014;123:351-73
pubmed: 25081536
Front Physiol. 2013 Jul 12;4:178
pubmed: 23874303
Biochim Biophys Acta. 2012 Aug;1818(8):1993-2001
pubmed: 22155212
Mol Med Rep. 2015 Nov;12(5):7419-24
pubmed: 26458866
Onco Targets Ther. 2017 Oct 27;10:5219-5228
pubmed: 29138574
Cancers (Basel). 2021 Oct 05;13(19):
pubmed: 34638469
PLoS One. 2011;6(7):e22567
pubmed: 21811634
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Cancer Lett. 2015 Jul 10;363(1):46-59
pubmed: 25843295
Front Immunol. 2013 Jan 11;3:420
pubmed: 23335924
Biosci Rep. 2015 Nov 24;36(1):e00283
pubmed: 26604323
Mol Clin Oncol. 2021 Sep;15(3):189
pubmed: 34349989
Int J Mol Sci. 2018 Apr 26;19(5):
pubmed: 29701678
Oncoimmunology. 2015 Aug 28;5(2):e1078056
pubmed: 27057452
Front Cell Dev Biol. 2018 Jun 07;6:59
pubmed: 29930939
Semin Cancer Biol. 2017 Jun;44:10-24
pubmed: 28257956
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
J Surg Oncol. 2019 Mar;119(3):370-378
pubmed: 30548537
Biomedicines. 2023 Mar 02;11(3):
pubmed: 36979746
Antioxid Redox Signal. 2009 Feb;11(2):323-38
pubmed: 18834328
Cell Tissue Res. 2016 Sep;365(3):495-506
pubmed: 27461257
Biochim Biophys Acta Biomembr. 2018 Jan;1860(1):83-90
pubmed: 28414037
Cell Mol Life Sci. 2013 Apr;70(7):1207-20
pubmed: 22918484
Nat Rev Cancer. 2010 Jun;10(6):435-41
pubmed: 20495577
Front Oncol. 2019 Dec 19;9:1446
pubmed: 31921691
J Cell Biol. 1967 May;33(2):235-42
pubmed: 6039368
Hum Mol Genet. 2013 Jun 1;22(11):2221-33
pubmed: 23420013